Annex Advisory Services LLC Purchases 1,221 Shares of Edwards Lifesciences Co. (NYSE:EW)

Annex Advisory Services LLC lifted its position in Edwards Lifesciences Co. (NYSE:EW) by 29.1% during the 4th quarter, Holdings Channel reports. The firm owned 5,421 shares of the medical research company’s stock after acquiring an additional 1,221 shares during the period. Annex Advisory Services LLC’s holdings in Edwards Lifesciences were worth $401,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Clarius Group LLC grew its holdings in shares of Edwards Lifesciences by 9.1% in the fourth quarter. Clarius Group LLC now owns 4,847 shares of the medical research company’s stock worth $359,000 after purchasing an additional 404 shares during the last quarter. Aaron Wealth Advisors LLC lifted its stake in Edwards Lifesciences by 52.1% in the fourth quarter. Aaron Wealth Advisors LLC now owns 6,288 shares of the medical research company’s stock worth $466,000 after acquiring an additional 2,155 shares during the period. Bowman & Co S.C. lifted its stake in Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after acquiring an additional 148 shares during the period. Kera Capital Partners Inc. purchased a new stake in Edwards Lifesciences in the fourth quarter worth $218,000. Finally, Merit Financial Group LLC lifted its stake in Edwards Lifesciences by 30.9% in the fourth quarter. Merit Financial Group LLC now owns 5,581 shares of the medical research company’s stock worth $413,000 after acquiring an additional 1,316 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wolfe Research lowered Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target for the company. in a research note on Thursday, January 16th. Citigroup raised their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Evercore ISI lowered their price objective on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Finally, Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Price Performance

NYSE EW opened at $69.77 on Tuesday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The stock has a 50-day moving average of $72.06 and a 200 day moving average of $71.18. The company has a market capitalization of $41.15 billion, a price-to-earnings ratio of 10.07, a PEG ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period last year, the company earned $0.59 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,000 shares of company stock worth $2,195,180 in the last three months. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.